ADVENTRX PHARMACEUTICALS INC has a total of 35 patent applications. Its first patent ever was published in 2004. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are CORTICE BIOSCIENCES INC, BLIGHT ANDREW R and PHARMANEUROBOOST N V.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 6 | |
#2 | WIPO (World Intellectual Property Organization) | 6 | |
#3 | EPO (European Patent Office) | 5 | |
#4 | Australia | 4 | |
#5 | Canada | 4 | |
#6 | China | 4 | |
#7 | Israel | 2 | |
#8 | Republic of Korea | 2 | |
#9 | Mexico | 1 | |
#10 | Taiwan | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Acyclic or carbocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Chen Andrew Xian | 10 |
#2 | Robbins Joan M | 9 |
#3 | Cantwell Mark J | 9 |
#4 | Robbins Joan | 8 |
#5 | Waninger Shani | 7 |
#6 | Chen Andrew X | 6 |
#7 | Ramos Silvestri | 5 |
#8 | Wu Hongjie | 5 |
#9 | Emanuele Martin | 2 |
#10 | Chen Adrew Xian | 1 |
Publication | Filing date | Title |
---|---|---|
WO2008109349A1 | Improved regimen for treating cancer with 5-fluorouracil, 5,10-methylenetetrahydrofolate and capecitabine | |
CA2651988A1 | Pharmaceutical compositions for vein irritating drugs | |
US2008045482A1 | Compositions and methods for the treatment of viral infections | |
CN101321518A | Stable pharmaceutical compositions of 5,10 methylenetetrahydrofolate | |
AU2006220459A1 | The use of thiophosphonoformic acid and NRTIs to treat viral infections | |
CN1942189A | Use of 5,10-methylene tetrahydrofolate for the treatment of cancer | |
US2007280944A1 | Use of 5,10-Methylene Tetrahydrofolate for the Treatment of Cancer | |
US2005232895A1 | Anti-viral pharmaceutical compositions | |
US2006008480A1 | Compositions for delivering highly water soluble drugs |